Naltrexone Hydrochloride

盐酸纳曲酮

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameNaltrexone Hydrochloride
Drug Alias Name环丙甲羟二氢吗啡酮(-)-Naltrexone hydrochlorideNaltrexonum盐酸环丙甲羟二羟吗啡酮纳酮 +[35] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMu opioid receptor antagonists
TargetsMu opioid receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeBorderline Personality Disorder +[66] 
Global Approved IndicationsOpioid-Related DisordersAlcoholism
Approved Indications in ChinaOpioid-Related Disorders
Original Approved Country/TerritoryUnited States
Original Approved Date1984/11/20
Country/TerritoryCanadaUnited StatesNew Zealand +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTeva
China Registration ClassN/A

Develop Information

Active CompaniesWomen'S Health Research Institute Of British ColumbiaCanadian Institutes Of Health Research (Cihr)University Of California San Francisco +[25] 
Inactive CompaniesDana-Farber Cancer InstituteShenzhen Civil Life Science Co LtdCentro Universitario La Salle +[36] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeBulimia Nervosa +[29] 
Inactive IndicationsBorderline Personality DisorderDevelopmental DisabilitiesDissociative Disorders +[37] 

Other Information

ATC CodeN07BB04
Related LinksWikipediaDrugBankKEGG